The World Anti-Doping Agency (WADA) announces the publication of the following Technical Letters, which were approved by the Agency’s Executive Committee on 4 November 2019 and are required to be implemented with immediate effect by all WADA-accredited laboratories:
This new Technical Letter includes guidance regarding the interpretation and reporting of findings for 6-oxo and metabolites, which may result in urine samples from the in-situ transformation of dehydroepiandrosterone (DHEA).
This revised version of TL08 reintroduces an explanatory sentence at the beginning of Section 3 - Additional Recommendation for Qualitative Confirmation Procedures. However, since the technical content has not changed from TL01/2017 (version 2.0), the effective date remains the same as said version.
This revised version of TL19 rectifies a typographical error in the second paragraph (page 1), and now properly refers to TL10 instead of TL09.
About Technical Letters
WADA publishes Technical Letters on an ad-hoc basis in order to provide instruction and guidance to WADA-accredited laboratories, WADA-approved laboratories for the Athlete Biological Passport and other stakeholders on particular issues related to the analysis, interpretation and reporting of results for specific Prohibited Substance(s) and/or Prohibited Method(s) or on the application of specific laboratory procedures. Technical Letters are modified and/or withdrawn by WADA as deemed appropriate.
The Technical Letters constitute a WADA laboratory standard document which supersedes any previous publication on a similar topic and becomes an integral part of the International Standard for Laboratories (ISL).
A Technical Letter shall be applied to samples which are received by the Laboratory on and after the Technical Letter’s effective date.
Should you have any questions regarding the above Technical Letters, we kindly invite you to contact WADA’s Science Department at . Should you wish to consult , they are available and on WADA’s website.